Blood-derived haematopoietic cell transplants: blood to blood?
Blood-derived haematopoietic cell transplants: blood to blood?
复制标题
血源性造血细胞移植：血对血？
DOI：
10.1016/0140-6736(91)91583-g
复制
发表时间：
1991
期刊：
影响因子：
--
通讯作者：
Gale,RP
中科院分区：
文献类型：
--
作者：
Henon,PR;Butturini,A;Gale,RP
结论：血液来源的细胞移植越来越多地用于癌症患者，替代骨髓移植或与骨髓移植联合使用。血液来源的细胞移植似乎可以加速高剂量化疗和/或放疗后的短期造血恢复;长期造血可能无法恢复，但如果短期效果允许恢复足够数量的受体干细胞，则可能是不必要的。对于某些肿瘤，血液来源的细胞移植可能比骨髓移植更不可能将肿瘤细胞返回给接受者。然而，即使找到证据支持这一理论，在更有效的移植前治疗方案出现之前，它可能并不具有临床重要性。血液、骨髓和脐带血来源的细胞的相对效用需要在随机对照试验中仔细评估。
Conclusions Transplants of blood-derived cells are increasingly used in patients with cancer, in place of or combined with bone-marrow transplants. Blood-derived cell transplants seem to accelerate short-term haematopoietic recovery after high-dose chemotherapy and/or radiation; long-term haematopoiesis may not be restored, but may be unnecessary if the short-term effects allow recovery of adequate numbers of recipient stem cells. Transplants of blood-derived cells may be less likely to return neoplastic cells to recipients than bone-marrow transplants for some tumours. However, even if evidence is found to support this theory it may not be clinically important until more effective antineoplastic pretransplant regimens are available. The relative utility of blood-derived, bone-marrow, and cordblood-derived cells needs careful assessment in randomised, controlled trials.